# Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities

> **NCT05349383** · — · COMPLETED · sponsor: **Central South University** · enrollment: 24618 (actual)

## Conditions studied

- Sepsis (SMQ)
- Opportunistic Infections
- Agranulocytosis

## Interventions

- **DRUG:** Antibody-Drug Conjugate
- **DRUG:** Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate

## Key facts

- **NCT ID:** NCT05349383
- **Lead sponsor:** Central South University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-22
- **Primary completion:** 2022-05-22
- **Final completion:** 2022-06-01
- **Target enrollment:** 24618 (ACTUAL)
- **Last updated:** 2022-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05349383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05349383, "Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05349383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*